The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - Blood, 2016 - research.sahmri.org.au
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - …, 2016 - pubmed.ncbi.nlm.nih.gov
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
[HTML][HTML] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - Blood, 2016 - ncbi.nlm.nih.gov
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
[HTML][HTML] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - Blood, 2016 - Elsevier
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
[PDF][PDF] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - 2016 - researchgate.net
Despite the extraordinary success of imatinib for the treatment of chronic myeloid leukemia
(CML), up to 40% of patients experience intolerance or resistance. The most common …
(CML), up to 40% of patients experience intolerance or resistance. The most common …
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
WT Parker, DT Yeung, AL Yeoman, HK Altamura… - Blood, 2016 - europepmc.org
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
[PDF][PDF] The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
WT Parker, DTO Yeung, AL Yeoman, HK Altamura… - 2016 - academia.edu
Despite the extraordinary success of imatinib for the treatment of chronic myeloid leukemia
(CML), up to 40% of patients experience intolerance or resistance. The most common …
(CML), up to 40% of patients experience intolerance or resistance. The most common …
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
WT Parker, DT Yeung, AL Yeoman, HK Altamura… - Blood, 2016 - europepmc.org
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …
common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant …